Stock 1093 CSPC PHARMACEUTICAL GROUP LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights CSPC Pharmaceutical Group Ltd.

Equities

1093

HK1093012172

Delayed Hong Kong S.E.
Other stock markets
 10:16:16 2024-05-23 pm EDT 		5-day change 1st Jan Change
6.4 HKD -0.62% Intraday chart for CSPC Pharmaceutical Group Ltd. -3.47% -11.98%
May. 17 CSPC Pharma Gets Clearance for China Clinical Trial of Drug for Metabolism-Related Diseases MT
May. 17 CSPC Pharmaceutical Group Limited Announces Recombinant Fully Human Anti-bKlotho Monoclonal Antibody Drug Obtains Approval from National Medical Products Administration of the People's Republic of China CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CSPC Pharma Gets Clearance for China Clinical Trial of Drug for Metabolism-Related Diseases
MT
CSPC Pharmaceutical Group Limited Announces Recombinant Fully Human Anti-bKlotho Monoclonal Antibody Drug Obtains Approval from National Medical Products Administration of the People's Republic of China
CI
CSPC Pharma's Flu Medication Gets Registration Approval in China
MT
Cspc Pharmaceutical Group Limited Announces That the Peramivir Injection (15Ml:0.15G) (The "Product") Developed by the Group Has Obtained Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China, and Is Deemed to Have Passed the Consistency Evaluation of Quality and Efficacy for Generic Drugs
CI
CSPC Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023
CI
CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor Obtains Clinical Trial Approval in the U.S
CI
CSPC Pharmaceutical's EBT Buys 8.5 Million Shares
MT
CSPC Pharmaceutical Group Limited and CSPC Holdings Company Limited Enter into Master Sales Agreement
CI
China's drugmakers can't sell mRNA shots but haven't quit yet
RE
CSPC Pharmaceutical Group Limited commences an Equity Buyback Plan for 1,190,321,973 shares, representing 10% of its issued share capital, under the authorization approved on May 31, 2023.
CI
CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval Granted by the National Medical Products Administration
CI
CSPC Pharmaceutical Group Limited Announces Dapagliflozin Tablets Obtains Drug Registration Approval
CI
CSPC Pharmaceutical's Cancer Drug Gets China Nod for Clinical Trials
MT
CSPC Pharmaceutical Group Limited Announces Antibody-Drug Conjugate SYS6023 Obtains Clinical Trial Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China
CI
CSPC Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 26 June 2024
CI
CSPC Pharmaceutical's Profit Falls 4% on Lower Revenue, Misses Estimates
MT
CSPC Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023
CI
CSPC Pharma Obtains Clinical Trial Approval in China for Anti-Tumor Drug
MT
CSPC Pharmaceutical Group Limited Announces Highly Selective MAT2A Inhibitor Obtains Clinical Trial Approval from the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China
CI
CSPC Pharmaceutical Obtains New Indication Nod for Mingfule Injection
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1093 Stock
  4. News CSPC Pharmaceutical Group Ltd.
  5. Highlights